Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. (Q47868775)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Peter A Argenta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Inhwa Um

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Charlene Kay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Dana Faratian

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Thanasak Sueblinvong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Melissa A Geller

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Simon P Langdon

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

30 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

368-373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

Cancer biomarkers: selecting the right drug for the right patient

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Automated subcellular localization and quantification of protein expression in tissue microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Estrone sulfatase activity in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Vimentin DNA methylation predicts survival in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Phase II trial of anastrozole in women with asymptomatic müllerian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.099

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2013.07.099

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23911795%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference